Open-label quetiapine in the treatment of children and adolescents with autistic disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 9, Issue 2, 1999, Pages 99-107

  Martin, Andrés ^a   Koenig, Kathleen ^a   Scahill, Lawrence ^a   Bregman, Joel ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

QUETIAPINE;

ADOLESCENT; APPETITE DISORDER; ARTICLE; AUTISM; BEHAVIOR DISORDER; CHILD; CHILD PSYCHIATRY; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; MALE; MENTAL DEFICIENCY; SEIZURE; SOMNOLENCE;

EID: 0032776490     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.1999.9.99     Document Type: Article

References (39)

1. Aman MG, Richmond G, Stewart AW, Bell JC, Kissel RC: The aberrant behavior checklist: Factor structure and the effect of subject variables in American and New Zealand facilities. Am J Ment Defic 91:570-578, 1987
2. Aman MG, Singh NN, Stewart AW, Field CJ: The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89:485-491, 1985a
3. Aman MG, Singh NN, Stewart AW, Field CJ: Psychometric characteristics of the aberrant behavior checklist. Am J Ment Defic 89:492-502, 1985b
4. Anderson GM, Horne WC, Chatterjee D, Cohen DJ: The hyperserotonemia of autism. Ann N Y Acad Sci 600:331-342, 1990
5. Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J: The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 19:227-239, 1989
6. Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH: Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. Am J Psychiatry 141:1195-1202, 1984
7. American Psychiatric Association (1994), Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington, D.C.: American Psychiatric Association
8. Borison RL, Arvanitis LA, Miller BG: ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol 16:158-69, 1996
9. Campbell M, Anderson LT, Meier M, et al.: A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 17:640-655, 1978
10. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE: Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 36:835-843, 1997
11. Cook EH, Courchesne R, Lord C, et al.: Evidence of linkage between the serotonin transporter and autistic disorder. Molecular Psychiatry 2:247-250, 1997
12. Freeman BJ, Ritvo ER, Yokota A, Ritvo A: A scale for rating symptoms of patients with the syndrome of autism in real life settings. J Am Acad Child Psychiatry 25:130-136, 1986
13. Goldstein JM, Arvanitis LA: ICI 204,636 (Seroquel): A dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and highlights of phase II clinical trials. CNS Drug Reviews 1:50-73, 1995
14. Goodman WK, Price LH, Rasmussen SA, et al.: The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 46:1012-1016, 1989a
15. Goodman WK, Price LH, Rasmussen SA, et al.: The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46:1006-1011, 1989b
16. Guy W: ECDEU Assessment Manual for Psychopharmacology. Washington, D.C.: US Department of Health, Education, and Welfare, Publication 76-338, pp 218-222, 1976
17. Le Couteur A, Rutter M, Lord C, et al.: Autism Diagnostic Interview: A semistructured interview for parents and caregivers of autistic persons. Journal of Autism and Developmental Disorders 19:363-387, 1989
18. Leiter RG: Leiter International Performance Scale. Chicago, Illinois: Stoelting, 1948
19. Levine J, Schooler NR: SAFTEE: A technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 22:343-381, 1986
20. Locascio JJ, Malone RP, Small AM, et al.: Factors related to haloperidol response and dyskinesias in autistic children. Psychopharmacol Bull 27:119-126, 1991
21. Lord C, Rutter M, Goode S, et al.: Autism Diagnostic Observation Schedule: A standardized observation of communicative and social behavior. J Autism Dev Disord 19:185-212, 1989
22. Malone RP, Ernst M, Godfrey KA, Locascio JJ, Campbell M: Repeated episodes of neuroleptic-related dyskinesias in autistic children. Psychopharmacol Bull 27:113-117, 1991
23. McBride PA, Anderson GM, Hertzig ME, et al.: Serotonergic responsivity in male young adults with autistic disorder. Results of a pilot study [published erratum appears in Arch Gen Psychiatry 1989 May;46(5):400]. Arch Gen Psychiatry 46:213-221, 1989
24. McDougle CJ, Holmes JP, Bronson MR, et al.: Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective open-label study. J Am Acad Child Adolesc Psychiatry 36:685-693, 1997
25. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH: A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders [see comments]. Arch Gen Psychiatry 55:633-641, 1998
26. McDougle CJ, Naylor ST, Cohen DJ, Aghajanian GK, Heninger GR, Price LH: Effects of tryptophan depletion in drug-free adults with autistic disorder [see comments]. Arch Gen Psychiatry 53:993-1000, 1996a
27. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH: A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53:1001-1008, 1996b
28. Potenza MN, McDougle CT: The role of serotonin in autistic-spectrum disorders. CNS Spectrums 2:25-42, 1997
29. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ: Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study. J Clin Psychopharmacol 19:37-44, 1999
30. Rapoport JL, Connors C, Reatig N: Rating scales and assessment instruments for use in pediatric psychopharmacology. Psychopharmacology Bulletin 21:713-1111, 1985
31. Rubin M: Use of atypical antipsychotics in children with mental retardation, autism, and other developmental disabilities. Psychiatric Annals 27:219-221, 1997
32. Scahill L, Riddle MA, McSwiggin-Hardin M, et al.: Children's Yale-Brown Obsessive Compulsive Scale: Reliability and validity. J Am Acad Child Adolesc Psychiatry 36:844-852, 1997
33. Schain RJ, Freedman DX: Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr 58:315-320, 1961
34. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG: Quetiapine in patients with schizophrenia. A high-and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 54:549-557, 1997
35. Sparrow S, Balla D, Cicchetti D: Vineland Adaptive Behavior Scales (Expanded Edition). Circle Pines, MN: American Guidance Service, 1984
36. Volkmar FR, Nelson DS: Seizure disorders in autism. J Am Acad Child Adolesc Psychiatry 29:127-129, 1990
37. Wechsler D: Manual for the Wechsler Intelligence Scale-Revised (3rd ed). San Antonio, Texas: Psychological Corporation, 1991
38. World Health Organization: International Classification of Diseases: Diagnostic Criteria for Research, 10th Edition. Geneva: World Health Organization, 1993
39. Zuddas A, Ledda MG, Fratta A, Muglia P, Cianchetti C: Clinical effects of clozapine on autistic disorder [letter]. Am J Psychiatry 153:738, 1996